According to Stock Rover* in the trailing 1-year, the Dividend Kings have returned +22.1% (blue line) compared to +37.1% for the S&P 500 Index benchmark (red line), as seen in the chart below ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham from Citi reiterated a Buy rating on the stock and has a $ ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

Neuroscience is a key area of focus for AbbVie. In addition to emraclidine, through the Cerevel acquisition AbbVie gained a neuroscience pipeline of multiple clinical-stage and preclinical ...

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...